| 替比夫定与阿德福韦酯治疗HBeAg阳性慢性乙型肝炎的疗效观察 |
| |
| 引用本文： | 占国清,谭华炳,李儒贵,李芳,谢杏榕. 替比夫定与阿德福韦酯治疗HBeAg阳性慢性乙型肝炎的疗效观察[J]. 实用肝脏病杂志, 2011, 14(1): 23-24,49. DOI: 10.3969/j.issn.1672-5069.2011.01.008 |
| |
| 作者姓名： | 占国清 谭华炳 李儒贵 李芳 谢杏榕 |
| |
| 作者单位： | 湖北医药学院附属人民医院肝病研究所,湖北省十堰市,442000 |
| |
| 摘 要： | 目的比较替比夫定与阿德福韦酯治疗HBeAg阳性慢性乙型肝炎的疗效和安全性。方法 175例HBeAg阳性慢性乙型肝炎患者被随机分为替比夫定组（85例）和阿德福韦酯组（90例）,比较两组在治疗后48周时的疗效。结果治疗后12周、24周、36周和48周时,替比夫定治疗患者HBV DNA水平低于阿德福韦酯组（P〈0.01）,HBV DNA转阴率和ALT复常率均高于阿德福韦酯组（P〈0.05或P〈0.01）;治疗后12周、24周和36周HBeAg转阴或血清学转换率和完全应答率也高于阿德福韦酯组（P〈0.05或P〈0.01）;治疗48周,替比夫定组有2例,阿德福韦酯组有1例出现病毒学反弹;两组均有良好的安全性。结论替比夫定较阿德福韦酯有更强的抑制HBV作用,其治疗可提高HBeAg转阴或血清学转换率和完全应答率。
|
| 关 键 词： | 慢性乙型肝炎 替比夫定 阿德福韦酯 疗效 |
Comparison of telbivudine and adefovir dipivoxil in the treatment of patients with HBeAg-positive chronic hepatitis B |
| |
| ZHAN Guoqing,TAN Huabing,LI Rugui,et al.. Comparison of telbivudine and adefovir dipivoxil in the treatment of patients with HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2011, 14(1): 23-24,49. DOI: 10.3969/j.issn.1672-5069.2011.01.008 |
| |
| Authors: | ZHAN Guoqing TAN Huabing LI Rugui et al. |
| |
| Affiliation: | ZHAN Guoqing,TAN Huabing,LI Rugui,et al.Institute of Hepatology,People's Hospitol,Hubei Medicine College,Shiyan 442000,Hubei Province,China |
| |
| Abstract: | Objective To compare the efficacy and safety of telbivudine(LdT)and ADV in the treatment of patients with HBeAg-positive CHB.Methods 175 patients with HBeAg-positive CHB were randomly divided into LdT group(n=85 cases)and ADV group(n=90 cases),and the observation was 48 weeks.Results Compared with the ADV group,the LdT group had a very lower serum HBV DNA levels(P<0.01)and higher HBV DNA negative and ALT normalization rates at week 12,24,36 and 48(P<0.05 or P<0.01);HBeAg negative or HBeAg/anti-HBe conversio... |
| |
| Keywords: | Hepatitis B Telbivudine Adefovir dipivoxil HBeAg |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
